ZLDAF (Zelira Therapeutics) 3-Month Share Buyback Ratio: 0.00% (As of Jun. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLDAF Zelira Therapeutics Ltd ZLDAF
1 GF Score
Price $0.26
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics 3-Month Share Buyback Ratio?

Zelira Therapeutics ZLDAF 1 3-Month Share Buyback Ratio is 0.00 as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 1/100. The stock has 7 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

ZLDAF
1GF Score
Zelira Therapeutics Ltd ZLDAF
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Zelira Therapeutics (ZLDAF) has a 3-Month Share Buyback Ratio of 0.00 as of Jun. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' 3-Month Share Buyback Ratio too high?
Zelira Therapeutics' current 3-Month Share Buyback Ratio is 0.00. Overall, Zelira Therapeutics has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' 3-Month Share Buyback Ratio compare to GNPX and SXTP?
Zelira Therapeutics' 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Zelira Therapeutics and its competitors. Zelira Therapeutics's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ZLDAF) has a current 3-Month Share Buyback Ratio of 0.00. The current 3-Month Share Buyback Ratio is 0.00. Zelira Therapeutics' overall GF Score™ is 1/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current 3-Month Share Buyback Ratio is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
1GF Score

Get the complete analysis for ZLDAF

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price